Skip to main content
Erschienen in: Strahlentherapie und Onkologie 3/2012

01.03.2012 | Original article

The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization

verfasst von: M. Takagi, K. Sakata, MD, M. Someya, Y. Matsumoto, H. Tauchi, M. Hareyama, M. Fukushima

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

5-chloro-2,4-dihydroxypyridine (gimeracil) is a component of the oral fluoropyrimidine derivative S-1. Gimeracil was originally added to S-1 to yield prolonged 5-fluorouracil (5-FU) concentrations in serum and tumor tissues by inhibiting dihydropyrimidine dehydrogenase, which degrades 5-FU. We previously demonstrated that gimeracil enhances the efficacy of radiotherapy through the suppression of homologous recombination (HR) in DNA double strand repair. The goal of this paper was to examine the effects of gimeracil on the sensitivity of anticancer drugs and hyperthermia in order to obtain effective radiosensitization.

Materials and methods

Various cell lines, including DLD 1 (human colon carcinoma cells) and cells deficient in HR or nonhomologous end-joining (NHEJ), were used in clonogenic assays. The survival of these cells after various treatments (e.g., drug treatment, heat treatment, and radiation) was determined based on their colony-forming ability.

Results

Gimeracil enhanced cell-killing effects of camptothecin (CPT), 5-FU, and hydroxyurea. Gimeracil sensitized effects of CPT or 5-FU to cells deficient in HR or NHEJ to a similar extent as in other cells (DLD1 and a parent cell), indicating that its sensitizing mechanisms may be different from inhibition of HR or NHEJ. Combination of gimeracil and CPT or 5-FU sensitized radiation more effectively than each modality alone. Gimeracil also enhanced heat sensitivity at 42°C or more. The degree of heat sensitization with gimeracil increased as the temperature increased, and the combination of gimeracil and heat-sensitized radiation was more effective than each modality alone.

Conclusion

Gimeracil enhanced sensitivity of CPT, 5-FU, and hyperthermia. Combination of these modalities sensitized radiation more efficiently than each modality alone.
Literatur
1.
Zurück zum Zitat Eder-Czembirek C, Erovic BM, Czembirek C et al (2010) Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 186:143–148PubMedCrossRef Eder-Czembirek C, Erovic BM, Czembirek C et al (2010) Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 186:143–148PubMedCrossRef
2.
Zurück zum Zitat Ferrara L, Kmiec EB (2004) Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cell by inducing DNA damage and activating homologous recombination. Nucleic Acids Res 32:5239–5248PubMedCrossRef Ferrara L, Kmiec EB (2004) Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cell by inducing DNA damage and activating homologous recombination. Nucleic Acids Res 32:5239–5248PubMedCrossRef
3.
Zurück zum Zitat Fuller LF, Painter RB (1988) A Chinese hamster ovary cell line hypersensitive to ionizing radiation and deficient in repair replication. Mutat Res 193:109–121PubMed Fuller LF, Painter RB (1988) A Chinese hamster ovary cell line hypersensitive to ionizing radiation and deficient in repair replication. Mutat Res 193:109–121PubMed
4.
Zurück zum Zitat Hall EJ (2006) Cell, tissue, and tumor kinetics. In: Hall EJ, Giaccia AM (eds) Radiobiology for the radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp16–29 Hall EJ (2006) Cell, tissue, and tumor kinetics. In: Hall EJ, Giaccia AM (eds) Radiobiology for the radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp16–29
5.
Zurück zum Zitat Harada K, Sato M, Ueyama Y et al (2008) Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs 19(1):85–90PubMedCrossRef Harada K, Sato M, Ueyama Y et al (2008) Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs 19(1):85–90PubMedCrossRef
6.
Zurück zum Zitat Hayashi T, Tanaka G, Irimura K et al (1996) Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo. J Toxicol Sci 21(Suppl 3):495–504PubMedCrossRef Hayashi T, Tanaka G, Irimura K et al (1996) Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo. J Toxicol Sci 21(Suppl 3):495–504PubMedCrossRef
7.
Zurück zum Zitat Helleday T, Lo J, Gent DC van et al (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6(7):923–935 Helleday T, Lo J, Gent DC van et al (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6(7):923–935
8.
Zurück zum Zitat Kawahara M, Furuse K, Segawa Y et al (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85(7):939–943PubMedCrossRef Kawahara M, Furuse K, Segawa Y et al (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85(7):939–943PubMedCrossRef
9.
Zurück zum Zitat Klenke FM, Abdollahi A, Bischof M et al (2011) Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol 187:45–51PubMedCrossRef Klenke FM, Abdollahi A, Bischof M et al (2011) Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol 187:45–51PubMedCrossRef
10.
Zurück zum Zitat Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221PubMedCrossRef Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221PubMedCrossRef
11.
Zurück zum Zitat Mantel F, Frey B, Haslinger S et al (2010) Combination of ionizing irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells. Strahlenther Onkol 186:587–599PubMedCrossRef Mantel F, Frey B, Haslinger S et al (2010) Combination of ionizing irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells. Strahlenther Onkol 186:587–599PubMedCrossRef
12.
Zurück zum Zitat Ohuchida A, Kouchi Y, Sato S et al (1996) Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo. J Toxicol Sci 21(Suppl 3):675–689PubMedCrossRef Ohuchida A, Kouchi Y, Sato S et al (1996) Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo. J Toxicol Sci 21(Suppl 3):675–689PubMedCrossRef
13.
Zurück zum Zitat Rades D, Nadrowitz R, Buchmann I et al (2010) Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlenther Onkol 186:458–462PubMedCrossRef Rades D, Nadrowitz R, Buchmann I et al (2010) Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlenther Onkol 186:458–462PubMedCrossRef
14.
Zurück zum Zitat Saito H, Grompe M, Neeley TL et al (1994) Fanconi anemia cells have a normal gene structure for topoisomerase I. Hum Genet 93:583–586PubMedCrossRef Saito H, Grompe M, Neeley TL et al (1994) Fanconi anemia cells have a normal gene structure for topoisomerase I. Hum Genet 93:583–586PubMedCrossRef
15.
Zurück zum Zitat Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820PubMedCrossRef Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820PubMedCrossRef
16.
Zurück zum Zitat Sanchez-Perez I (2006) DNA repair inihibitors in cancer treatment. Clin Transl Oncol 8:642–646PubMedCrossRef Sanchez-Perez I (2006) DNA repair inihibitors in cancer treatment. Clin Transl Oncol 8:642–646PubMedCrossRef
17.
Zurück zum Zitat Shinchi H, Maemura K, Noma H et al (2007) Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer 96(9):1353–1357PubMed Shinchi H, Maemura K, Noma H et al (2007) Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer 96(9):1353–1357PubMed
18.
Zurück zum Zitat Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557PubMedCrossRef Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557PubMedCrossRef
19.
Zurück zum Zitat Singleton BK, Priestley A, Steingrimsdottir H et al (1997) Molecular and biochemical characterization of xrs mutants defective in Ku80. Mol Cell Biol 17(3):1264–1273PubMed Singleton BK, Priestley A, Steingrimsdottir H et al (1997) Molecular and biochemical characterization of xrs mutants defective in Ku80. Mol Cell Biol 17(3):1264–1273PubMed
20.
Zurück zum Zitat Snyder RD (1984) The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea. Mutat Res 131:163–172PubMed Snyder RD (1984) The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea. Mutat Res 131:163–172PubMed
21.
Zurück zum Zitat Taccioli GE, Gottlieb TM, Blunt T et al (1994) Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science 265(5177):1442–1445PubMedCrossRef Taccioli GE, Gottlieb TM, Blunt T et al (1994) Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science 265(5177):1442–1445PubMedCrossRef
22.
Zurück zum Zitat Tahara M (2006) Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC). Jpn J Cancer Chemo 33(Suppl 1):167–171 Tahara M (2006) Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC). Jpn J Cancer Chemo 33(Suppl 1):167–171
23.
Zurück zum Zitat Takagi M, Sakata K, Someya M et al (2010) Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol 96:259–266PubMedCrossRef Takagi M, Sakata K, Someya M et al (2010) Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol 96:259–266PubMedCrossRef
24.
Zurück zum Zitat Takahashi A, Matsumoto H, Nagayama K et al (2004) Evidence for the involvement of double-strand breaks in heat-induced cell killing. Cancer Res 64:8839–8845PubMedCrossRef Takahashi A, Matsumoto H, Nagayama K et al (2004) Evidence for the involvement of double-strand breaks in heat-induced cell killing. Cancer Res 64:8839–8845PubMedCrossRef
25.
Zurück zum Zitat Takechi T, Fujioka A, Matsushima E et al (2002) Enhancement of the antitumour activityb of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38:1271–1277PubMedCrossRef Takechi T, Fujioka A, Matsushima E et al (2002) Enhancement of the antitumour activityb of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38:1271–1277PubMedCrossRef
26.
Zurück zum Zitat Tatsumi K, Fukushima M, Shirasaka T et al (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78(7):748–755PubMed Tatsumi K, Fukushima M, Shirasaka T et al (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78(7):748–755PubMed
27.
Zurück zum Zitat Van den Brande J, Schoffski P, Schellens JH et al (2003) EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88(5):648–653CrossRef Van den Brande J, Schoffski P, Schellens JH et al (2003) EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88(5):648–653CrossRef
Metadaten
Titel
The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization
verfasst von
M. Takagi
K. Sakata, MD
M. Someya
Y. Matsumoto
H. Tauchi
M. Hareyama
M. Fukushima
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 3/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-011-0043-6

Weitere Artikel der Ausgabe 3/2012

Strahlentherapie und Onkologie 3/2012 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Mitteilungen

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.